CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ProKidney Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ProKidney Corp
2000 Frontis Plaza Blvd., Suite 250
Phone: (336) 999-7028p:336 999-7028 WINSTON-SALEM, NC  27103  United States Ticker: PROKPROK
This company was Merged or Acquired on 7/12/2022.
This is a Subsidiary, click here for the Parent Company
Business Summary
ProKidney Corp. is a clinical-stage cellular therapeutics company. The Company is focused on cell therapy platforms capable of treating multiple chronic kidney diseases (CKD) using a patient’s own cells isolated from the patient intended for treatment. The Company’s lead product candidate, rilparencel, is designed to preserve kidney function in a CKD patient’s diseased kidneys. Rilparencel is a product that includes autologous selected renal cells (SRCs) prepared from a patient’s own (autologous) kidney cells. Rilparencel is an investigational product that includes a mixture of kidney cells prepared from the participant’s own kidney tissue. The SRC are formulated rilparencel for reinjection into the patient’s kidneys using a minimally invasive outpatient procedure that is repeatable, if necessary. It is conducting a global Phase III development program and multiple Phase II clinical trials for rilparencel in subjects with moderate to severe CKD and diabetes.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
6770 Blank checks

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board PabloLegorreta 60
Chief Executive Officer, Director BruceCulleton 56 11/15/2023 11/15/2023
Chief Financial Officer JamesCoulston 48 1/1/2022 1/1/2022
8 additional Officers and Directors records available in full report.

Business Names
Business Name
DNAC
PROK
ProKidney Acquisition Company II, LLC
ProKidney Acquisition Company, LLC
ProKidney Corp. GP Limited
ProKidney LP

General Information
Number of Employees: 204 (As of 12/31/2024)
Outstanding Shares: 292,697,649 (As of 3/17/2025)
Shareholders: 44
Stock Exchange: NASD
Federal Tax Id: 981586514


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 18, 2025